Yakult trial takes 4SC's resminostat into NSCLC
This article was originally published in Scrip
Executive Summary
Following the news in June that 4SC was cutting around 15% of its staff to reduce costs and focus resources on its lead development project resminostat (scripintelligence.com, 20 June 2013), it must come as some relief to the German biotech firm that the anticancer is now moving forward in a new indication in Japan.